Andrew John Mallett

List of Publications by Year
in descending order

79	1,479	361296 20	377752 34
papers	citations	h-index	g-index

84	84	84	2284
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A clinical approach to tubulopathies in children and young adults. Pediatric Nephrology, 2023, 38, 651-662.	0.9	5
2	Gitelman-Like Syndrome Caused by Pathogenic Variants in mtDNA. Journal of the American Society of Nephrology: JASN, 2022, 33, 305-325.	3.0	26
3	National and international kidney failure registries: characteristics, commonalities, and contrasts. Kidney International, 2022, 101, 23-35.	2.6	11
4	Genetics in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2022, 101, 1126-1141.	2.6	46
5	The prevalence of Fabry disease in a statewide chronic kidney disease cohort â€“ Outcomes of the aCQuiRE (Ckd.Qld fabRy Epidemiology) study. BMC Nephrology, 2022, 23, 169.	0.8	7
6	The Evolving Role of Diagnostic Genomics in Kidney Transplantation. Kidney International Reports, 2022, 7, 1758-1771.	0.4	6
7	The Heritability of Kidney Function Using an Older Australian Twin Population. Kidney International Reports, 2022, 7, 1819-1830.	0.4	4
8	Establishing a Core Outcome Set for Autosomal Dominant Polycystic Kidney Disease: Report of the Standardized Outcomes in Nephrologyâ€“Polycystic Kidney Disease (SONG-PKD) Consensus Workshop. American Journal of Kidney Diseases, 2021, 77, 255-263.	2.1	21
9	Multiple Cerebral Aneurysms in an Adult With Autosomal Recessive Polycystic Kidney Disease. Kidney International Reports, 2021, 6, 219-223.	0.4	8
10	Attitudes and Practices of Australian Nephrologists Toward Implementation of Clinical Genomics. Kidney International Reports, 2021, 6, 272-283.	0.4	28
11	Clinical impact of genomic testing in patients with suspected monogenic kidney disease. Genetics in Medicine, 2021, 23, 183-191.	1.1	70
12	Nephrology in Australia. , 2021, , 701-721.		0
13	Ciliopathies and the Kidney: A Review. American Journal of Kidney Diseases, 2021, 77, 410-419.	2.1	116
14	Australia and New Zealand renal gene panel testing in routine clinical practice of 542 families. Npj Genomic Medicine, 2021, 6, 20.	1.7	11
15	Per-Treatment Post Hoc Analysis of Clinical Trial Outcomes With Tolvaptan in ADPKD. Kidney International Reports, 2021, 6, 1032-1040.	0.4	0
16	MO1005ADPEDKD: A GLOBAL ONLINE PLATFORM TO EXPLORE THE CHILDHOOD PHENOTYPE OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE*. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	0
17	Clinical versus research genomics in kidney disease. Nature Reviews Nephrology, 2021, 17, 570-571.	4.1	4
18	Bleeding Complications of Percutaneous Kidney Biopsy: Does Gender Matter?. Kidney360, 2021, 2, 1308-1312.	0.9	5

#	Article	IF	Citations
19	Birt-Hogg-DubÃ© Syndrome and Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome: An Effective Multidisciplinary Approach to Hereditary Renal Cancer Predisposing Syndromes. Frontiers in Oncology, 2021, 11, 738822.	1.3	10
20	Clinical Outcomes of People With Fabry Disease â€" ANZDATA Registry Study. Kidney International Reports, 2021, 6, 2481-2485.	0.4	4
21	Cost-Effectiveness of Targeted Exome Analysis as a Diagnostic Test in Glomerular Diseases. Kidney International Reports, 2021, 6, 2850-2861.	0.4	15
22	Pharmacist-Led Education for Final Year Medical Students: A Pilot Study. Frontiers in Medicine, 2021, 8, 732054.	1.2	3
23	Multi-phenotype genome-wide association studies of the Norfolk Island isolate implicate pleiotropic loci involved in chronic kidney disease. Scientific Reports, 2021, 11, 19425.	1.6	1
24	Genomic diagnostics in polycystic kidney disease: an assessment of real-world use of whole-genome sequencing. European Journal of Human Genetics, 2021, 29, 760-770.	1.4	20
25	Monogenic Nephrolithiasisâ€"Collision of Phenotypes, Genotypes, and Phenocopies. Kidney International Reports, 2021, 6, 2737-2739.	0.4	0
26	Pilot clinical and validation study of the PROPKD score in clinical practice amongst patients with Autosomal Dominant Polycystic Kidney Disease. Nephrology, 2020, 25, 274-275.	0.7	2
27	Toward Transparency in Nephrology Research. Kidney International Reports, 2020, 5, 118-120.	0.4	0
28	Adult-Diagnosed Nonsyndromic Nephronophthisis in Australian Families Caused by Biallelic NPHP4 Variants. American Journal of Kidney Diseases, 2020, 76, 282-287.	2.1	8
29	ABO blood group relationships to kidney transplant recipient and graft outcomes. PLoS ONE, 2020, 15, e0236396.	1.1	3
30	DNAJB11-Related Atypical ADPKD in a Kidney Transplant Donor. Kidney International Reports, 2020, 5, 1363-1366.	0.4	4
31	Protocol and establishment of a Queensland renal biopsy registry in Australia. BMC Nephrology, 2020, 21, 320.	0.8	2
32	Genetic Kidney Disease in Southern Tasmania. Kidney International Reports, 2020, 5, 534-537.	0.4	1
33	Clinical and Healthcare Utilization Outcomes of Parathyroidectomy in CKD and Dialysis Patients. Kidney International Reports, 2020, 5, 1086-1089.	0.4	1
34	The Ckd. Qld fabRy Epidemiology (aCQuiRE) study protocol: identifying the prevalence of Fabry disease amongst patients with kidney disease in Queensland, Australia. BMC Nephrology, 2020, 21, 58.	0.8	9
35	Prevalence of Fabry disease in dialysis patients: Western Australia Fabry disease screening study - the FoRWARD study. Orphanet Journal of Rare Diseases, 2020, 15, 10.	1.2	16
36	Clinical spectrum, prognosis and estimated prevalence of DNAJB11-kidney disease. Kidney International, 2020, 98, 476-487.	2.6	38

#	Article	IF	Citations
37	A mutation affecting laminin alpha 5 polymerisation gives rise to a syndromic developmental disorder. Development (Cambridge), 2020, 147, .	1.2	28
38	Kidney transplant recipientâ€™s perceptions of blood testing through microsampling and venepuncture. Bioanalysis, 2020, 12, 873-881.	0.6	12
39	Isolated proteinuria due to CUBN homozygous mutation â€“ challenging the investigative paradigm. BMC Nephrology, 2019, 20, 330.	0.8	9
40	Precision Medicine Diagnostics for Rare Kidney Disease: Twitter as a Tool in Clinical Genomic Translation. Kidney Medicine, 2019, 1, 315-318.	1.0	4
41	ADPedKD: A Global Online Platform on the Management of Children With ADPKD. Kidney International Reports, 2019, 4, 1271-1284.	0.4	20
42	Genome-wide association study of medication-use and associated disease in the UK Biobank. Nature Communications, 2019, 10, 1891.	5.8	140
43	Treatment and long-term outcome in primary distal renal tubular acidosis. Nephrology Dialysis Transplantation, 2019, 34, 981-991.	0.4	75
44	Comprehensive evaluation of a prospective Australian patient cohort with suspected genetic kidney disease undergoing clinical genomic testing: a study protocol. BMJ Open, 2019, 9, e029541.	0.8	6
45	Proposed minimum information guideline for kidney diseaseâ€”research and clinical data reporting: a cross-sectional study. BMJ Open, 2019, 9, e029539.	0.8	1
46	Renal genetics in Australia: Kidney medicine in the genomic age. Nephrology, 2019, 24, 279-286.	0.7	18
47	An audit of electron microscopy in the diagnosis of focal segmental glomerulosclerosis: are current pathological techniques missing important abnormalities in the glomerular basement membrane?. F1000Research, 2019, 8, 1204.	0.8	1
48	Patient-iPSC-Derived Kidney Organoids Show Functional Validation of a Ciliopathic Renal Phenotype and Reveal Underlying Pathogenetic Mechanisms. American Journal of Human Genetics, 2018, 102, 816-831.	2.6	157
49	Paraneoplastic immunoglobulin A nephropathy and associated focal segmental glomerulosclerosis in asymptomatic low volume B-cell lymphoma â€“ a case report. BMC Nephrology, 2018, 19, 224.	0.8	3
50	Antenatally Diagnosed ADPKD. Kidney International Reports, 2018, 3, 1214-1217.	0.4	4
51	CFHR5 Nephropathy in a Greek-Cypriot Australian Family: Ancestry-Informed Precision Medicine. Kidney International Reports, 2018, 3, 1222-1228.	0.4	1
52	Recurrent atypical haemolytic uraemic syndrome post kidney transplant due to aCD46mutation in the setting ofSMARCAL1-mediated inherited kidney disease. Nephrology, 2017, 22, 11-14.	0.7	1
53	Monoclonal gammopathy of renal significance triggering atypical haemolytic uraemic syndrome. Nephrology, 2017, 22, 15-17.	0.7	10
54	Massively parallel sequencing and targeted exomes in familial kidney disease can diagnose underlyingÂgenetic disorders. Kidney International, 2017, 92, 1493-1506.	2.6	74

#	Article	IF	Citations
55	Mutations in mitochondrial DNA causing tubulointerstitial kidney disease. PLoS Genetics, 2017, 13, e1006620.	1.5	52
56	The increasing rates of acute interstitial nephritis in Australia: a single centre case series. BMC Nephrology, 2017, 18, 329.	0.8	12
57	A multidisciplinary renal genetics clinic improves patient diagnosis. Medical Journal of Australia, 2016, 204, 58-59.	0.8	31
58	KHAâ€CARI guideline recommendations for the diagnosis and management of autosomal dominant polycystic kidney disease. Nephrology, 2016, 21, 705-716.	0.7	26
59	Identifying and integrating consumer perspectives in clinical practice guidelines on autosomalâ€dominant polycystic kidney disease. Nephrology, 2016, 21, 122-132.	0.7	33
60	Polypoid Change of the Glomerular Basement Membrane in a Child with Steroid Resistant Nephrotic Syndrome and ARHGAP24 Mutation: A Case Report. The Open Urology & Nephrology Journal, 2016, 9, 88-93.	0.2	2
61	Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the <scp>A</scp>ustralian compassionate access cohort. Internal Medicine Journal, 2015, 45, 1054-1065.	0.5	25
62	End-Stage Kidney Disease Due to Fibrillary Glomerulonephritis and Immunotactoid Glomerulopathy - Outcomes in 66 Consecutive ANZDATA Registry Cases. American Journal of Nephrology, 2015, 42, 177-184.	1.4	26
63	A protocol for the identification and validation of novel genetic causes of kidney disease. BMC Nephrology, 2015, 16, 152.	0.8	8
64	Genomics in the renal clinic - translating nephrogenetics for clinical practice. Human Genomics, 2015, 9, 13.	1.4	12
65	Fibrillary glomerulonephritis: An apparent familial form?. Nephrology, 2015, 20, 506-509.	0.7	12
66	KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Genetics and Genetic Counseling. Seminars in Nephrology, 2015, 35, 550-556.e1.	0.6	5
67	KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Genetic Testing for Diagnosis. Seminars in Nephrology, 2015, 35, 545-549.e2.	0.6	10
68	KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Pharmacological Management. Seminars in Nephrology, 2015, 35, 582-589.e17.	0.6	9
69	KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Psychosocial Care. Seminars in Nephrology, 2015, 35, 590-594.e5.	0.6	2
70	KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Management of Renal Stone Disease. Seminars in Nephrology, 2015, 35, 603-606.e3.	0.6	11
71	KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Management of Polycystic Liver Disease. Seminars in Nephrology, 2015, 35, 618-622.e5.	0.6	14
72	End-stage kidney disease due to Alport syndrome: outcomes in 296 consecutive Australia and New Zealand Dialysis and Transplant Registry cases. Nephrology Dialysis Transplantation, 2014, 29, 2277-2286.	0.4	40

#	Article	IF	Citations
73	Atypical HUS associated with severe, unexpected antibody-mediated rejection post kidney transplant. Nephrology, 2014, 19, 22-26.	0.7	8
74	The prevalence and epidemiology of genetic renal disease amongst adults with chronic kidney disease in Australia. Orphanet Journal of Rare Diseases, 2014, 9, 98.	1.2	54
75	<scp>NOS3</scp> as a potential modifier of <scp>ADPKD</scp> phenotypic variability: Progress towards an answer. Nephrology, 2014, 19, 733-734.	0.7	1
76	Sustained remission of systemic lupus erythematosus related calciphylaxis. Lupus, 2012, 21, 441-444.	0.8	6
77	Ibuprofen-related renal tubular acidosis in pregnancy. Obstetric Medicine, 2011, 4, 122-124.	0.5	6
78	Metformin for preventing the progression of chronic kidney disease. The Cochrane Library, 0, , .	1.5	0
79	The HIDDEN Protocol: An Australian Prospective Cohort Study to Determine the Utility of Whole Genome Sequencing in Kidney Failure of Unknown Aetiology. Frontiers in Medicine, 0, 9, .	1.2	2